Trial Watch No. 12
Where Conviction Is Building, In Real Time
The second half of June 2026 delivers four defining shifts. Obesity competition widens as Roche, Boehringer Ingelheim, and Novo Nordisk open major obesity programs in the same window. BCMA in 1L multiple myeloma becomes a multi-asset race as Heidelberg's Teclistamab quintuplet follows Edition 11's Regeneron Linvoseltamab. FXI mAb expansion continues at mega scale with Regeneron's ROXI-CAT-II in cancer-associated VTE. And universal CAR T enters solid-tumor neurology with T-MAXIMUM's intracerebroventricular MT027 in recurrent GBM.
Summary Layer
The second half of June 2026 delivers four defining shifts. Obesity competition widens as Roche, Boehringer Ingelheim, and Novo Nordisk open major obesity programs in the same window. BCMA in 1L multiple myeloma becomes a multi-asset race: Heidelberg's Teclistamab quintuplet follows Edition 11's Regeneron Linvoseltamab into newly diagnosed transplant-eligible MM, placing daratumumab's 1L grip under simultaneous pressure.
FXI mAb expansion continues at mega scale; Regeneron's REGN7508 opens ROXI-CAT-II in cancer-associated VTE (1,600 patients) after the Edition 10 ROXI-PALISADE PAD program (7,050 patients). One sponsor, two mega Phase 3s on the same Factor XI antibody, two indications. Universal CAR T enters solid-tumor neurology with T-MAXIMUM's MT027 B7H3-targeted UCAR T with intracerebroventricular delivery in recurrent glioblastoma; a fundamentally new CAR T sub-category in CNS oncology.
15 high-signal trials across oncology, cardiometabolic, neurology, and advanced modalities. Each entry includes its ClinicalTrials.gov record, WHO ICTRP cross-listing, and the most relevant sponsor or study source available.
Therapeutic Areas Covered
Oncology
6 trialsROXI-CAT-II; REGN7508 vs. Apixaban for Treatment and Secondary Prevention of VTE in Solid + Hematologic Cancers
Regeneron's anti-FXI mAb opens a 1,600-patient Phase 3 in cancer-associated VTE
Timeline
Start: June 30, 2026. Primary completion: July 2031.
Mechanism
REGN7508, Regeneron's anti-Factor XI monoclonal antibody, tested against apixaban for treatment and secondary prevention of cancer-associated VTE. Same molecule as Edition 10's ROXI-PALISADE (PAD); now in a different indication.
Why It Matters
Cancer-associated VTE is a major unmet need; DOACs reduced bleeding versus warfarin but still carry meaningful bleeding risk in malignancy. FXI inhibition has been positioned as the cleanest anticoagulant biology since 2018. Regeneron now runs two mega Phase 3s on the same FXI mAb in different indications (7,050 PAD patients + 1,600 cancer VTE patients); total program commitment at 8,650 patients across two indications signals Regeneron believes FXI is the next anticoagulant standard.
Verified sources
TST001 + Pembrolizumab + Chemotherapy in Claudin18.2+ Locally Advanced or Metastatic Gastric / GEJ Adenocarcinoma
Transcenta's CLDN18.2 mAb enters Phase 3, layering IO onto the zolbetuximab framework
Timeline
Start: June 30, 2026. Primary completion: October 2029.
Mechanism
TST001 (Osemitamab) is Transcenta's anti-CLDN18.2 monoclonal antibody, tested 1L in combination with pembrolizumab and CAPOX/FOLFOX in Claudin18.2-positive gastric / GEJ adenocarcinoma.
Why It Matters
CLDN18.2 has emerged as the most promising gastric cancer target since HER2. Astellas's zolbetuximab (Vyloy) won 1L approval in 2024. Transcenta is the next challenger entering Phase 3; adds PD-1 blockade to the zolbetuximab framework, betting that IO synergy delivers superior outcomes. AstraZeneca and BeOne also have CLDN18.2 programs in late-stage development. Gastric cancer was a single-target indication until 2024; it is now a multi-asset CLDN18.2 race.
Verified sources
Teclistamab + Daratumumab + Lenalidomide + Bortezomib + Dexamethasone in Newly Diagnosed Transplant-Eligible MM
Heidelberg quintuplet follows Edition 11's Linvoseltamab into 1L MM
Timeline
Start: June 30, 2026. Primary completion: February 2031.
Mechanism
Adds teclistamab (Janssen's BCMAxCD3 bispecific, approved in r/r MM) to the daratumumab + lenalidomide + bortezomib + dexamethasone (Dara-VRd) backbone in newly diagnosed transplant-eligible multiple myeloma.
Why It Matters
Second BCMA bispecific moving into 1L MM in two consecutive editions; after Edition 11's Regeneron Linvoseltamab vs. DVRd Phase 2/3 (1,570 patients), Heidelberg now layers teclistamab onto Dara-VRd. Two big-pharma BCMA bispecifics opening 1L MM Phase 3s in 30 days. Daratumumab's 1L dominance is under simultaneous attack from two directions; and from two different sponsors with different framing approaches (Linvo replacing dara in DVRd; Teclistamab adding to Dara-VRd as quintuplet).
Verified sources
Sacituzumab Govitecan + Pembrolizumab vs. SoC Chemotherapy as Neoadjuvant in Stage II-III TNBC
WSG moves the Trodelvy + Keytruda combination from metastatic into curative-intent neoadjuvant TNBC
Timeline
Start: June 30, 2026. Primary completion: March 2033.
Mechanism
Sacituzumab govitecan (Trodelvy, Gilead); TROP2-directed ADC with TOP1 payload; combined with pembrolizumab in the neoadjuvant setting in clinical Stage II-III triple-negative early breast cancer. Dynamic biomarker-adjusted personalized therapy design.
Why It Matters
Moves the Trodelvy + Keytruda combination from metastatic TNBC into the curative-intent neoadjuvant setting; the single largest commercial expansion for the TROP2 ADC class. If positive, neoadjuvant TNBC standard of care shifts away from KEYNOTE-522 chemo+pembro toward ADC+pembro, potentially eliminating anthracycline exposure for many patients. WSG is an academically rigorous breast-cancer consortium; independent confirmation of Gilead/Merck data carries weight.
Verified sources
Mocertatug Rezetecan vs. Standard of Care in Platinum-Resistant Ovarian Cancer
GSK's ADC enters PROC Phase 3 alongside Edition 11's Genmab Rina-S
Timeline
Start: June 24, 2026. Primary completion: August 2030.
Mechanism
Mocertatug Rezetecan is GSK's antibody-drug conjugate (target undisclosed in registry), tested against investigator's choice (paclitaxel, PLD, topotecan, gemcitabine, bevacizumab, pembrolizumab) in platinum-resistant ovarian cancer.
Why It Matters
Second platinum-resistant ovarian Phase 3 in two editions; Genmab's Rina-S (FRα ADC) opened in Edition 11. Mocertatug is GSK's competitive entrant. Two ADCs entering PROC Phase 3 in 30 days reflects how thoroughly oncology has converged on ADC modality as the next decade's primary expansion category. Mirvetuximab (ImmunoGen / AbbVie) faces dual challenger pressure.
Verified sources
KANDLELIT-015; MK-1084 (Calderasib) + Durvalumab vs. Placebo + Durvalumab Post-CRT in KRAS G12C+ Stage III NSCLC
Merck moves the first KRAS G12C inhibitor into curative-intent Stage III NSCLC consolidation
Timeline
Start: June 18, 2026. Primary completion: December 2032.
Mechanism
MK-1084 (calderasib) is Merck's KRAS G12C inhibitor, run as consolidation therapy with durvalumab in patients with locally advanced KRAS G12C-mutant NSCLC who have not progressed after platinum-based chemoradiation.
Why It Matters
First KRAS G12C inhibitor moved into the curative-intent Stage III NSCLC setting; extending the PACIFIC durvalumab consolidation paradigm with targeted therapy. Mirati's adagrasib (acquired by BMS) and Amgen's sotorasib have struggled to expand beyond 2L metastatic NSCLC. If MK-1084 shows benefit in this consolidation setting, the entire KRAS G12C class moves into earlier disease; and Merck's biomarker-stratified development playbook gets validated again.
Verified sources
Cardiometabolic
4 trialsBAY 3670549 in Adults With Atrial Fibrillation
Bayer opens a 28-site novel-mechanism Phase 2 in AF
Timeline
Start: June 19, 2026. Primary completion: May 2030.
Mechanism
BAY 3670549 is Bayer's novel cardiometabolic agent for atrial fibrillation (target not yet disclosed). Multi-cohort dose-finding Phase 2 with parallel-group placebo control.
Why It Matters
Atrial fibrillation pharmacotherapy has been stuck on rate/rhythm control (beta-blockers, amiodarone, flecainide) and anticoagulation for decades. Bayer running a 28-site multi-cohort Phase 2 signals confidence in a novel AF target; the kind of high-conviction Phase 2 architecture that typically precedes a Phase 3 commitment. AF affects 60M people globally; any meaningfully novel rhythm-modulating mechanism would represent a meaningful platform shift.
Verified sources
CagriSema Presentation Comparability Study in Overweight or Obesity
Novo's fourth concurrent late-stage obesity Phase 3 supports launch device variants
Timeline
Start: June 22, 2026. Primary completion: November 2027.
Mechanism
Placebo-controlled comparability Phase 3 of two different presentations of CagriSema (the cagrilintide + semaglutide fixed-dose combination), supporting commercial launch device options.
Why It Matters
Novo's third active CagriSema Phase 3 in two editions (after Edition 10's CagriSema vs. Semaglutide head-to-head, 2,500 patients); now extending into device/presentation comparability for registration-enabling data. The 1,400-patient enrollment and 116-site footprint indicate Novo is operationally pre-positioning multiple device variants for launch. Combined with AMAZE 8 (Edition 10) and AMAZE 4 (Edition 9), Novo now has four parallel late-stage obesity Phase 3s in flight.
Verified sources
Petrelintide Co-Administered With Enicepatide (RO7795068) in Adults With Obesity or Overweight
Roche's amylin + GLP-1/GIP combo Phase 2 tests the Carmot platform's tirzepatide-or-better hypothesis
Timeline
Start: June 30, 2026. Primary completion: November 2027.
Mechanism
Roche's amylin analog (petrelintide, ex-Carmot Therapeutics) combined with enicepatide (RO7795068, Roche's once-weekly GLP-1/GIP agonist, also ex-Carmot CT-388 lineage). Dose-finding Phase 2 to identify optimal combination ratios.
Why It Matters
Roche's obesity entry now consists of two assets being tested in combination. After the $3.1B Carmot acquisition in 2023, this combination Phase 2 is Roche's first Phase 2 result that will indicate whether the amylin + GLP-1/GIP combo platform delivers tirzepatide-or-better weight loss. Roche is moving from a single-asset bet to a combination + monotherapy platform play in obesity.
Verified sources
BI 3034701; 42-Week Dose-Finding Phase 2b in Obesity / Overweight
Boehringer Ingelheim's first major fully-owned Phase 2b obesity entry
Timeline
Start: June 29, 2026. Primary completion: August 2027.
Mechanism
BI 3034701 is Boehringer's novel subcutaneous obesity asset (mechanism not yet disclosed). 42-week parallel-group dose-finding design designed to feed directly into Phase 3 commitment.
Why It Matters
Boehringer Ingelheim makes its first major Phase 2b obesity entry; joining a crowded late-stage obesity field spanning Novo, Lilly, Amgen, Pfizer, Roche, and BI. BI previously co-developed survodutide (GLP-1/glucagon) with Zealand Pharma; now they are moving a fully owned asset forward. 57-site Phase 2b infrastructure at start indicates BI has the operational capacity to move directly to Phase 3 if the readout is positive.
Verified sources
Neurology
2 trialsAlzheimer's Disease Tau Platform Clinical Trial; AADvac1 / Tau2 vs. Standard of Care
ATRI USC opens a 900-patient multi-arm Phase 2 platform on tau
Timeline
Start: June 30, 2026. Primary completion: August 2028.
Mechanism
Multi-arm Phase 2 platform trial testing tau-targeting therapeutics (AADvac1, Tau2) across preclinical, prodromal, and Alzheimer's disease populations. Platform design allows shared placebo arms and accelerated arm-by-arm readouts.
Why It Matters
Anti-amyloid antibodies (lecanemab, donanemab) have validated the amyloid hypothesis but delivered modest benefit. Tau is the next major Alzheimer's target; pathology more closely correlates with cognitive decline than amyloid. The Aisen group's platform design (modeled on master protocols in oncology) is the most ambitious tau trial yet. If AADvac1 or Tau2 deliver any meaningful cognitive benefit, the entire neurodegenerative therapeutic frontier shifts from amyloid clearance to tau-mediated disease modification.
Lu AF28996 in Adults With Parkinson's Disease Experiencing Motor Fluctuations
Lundbeck's new PD asset targets off-time without exacerbating dyskinesia
Timeline
Start: June 30, 2026. Primary completion: December 2028.
Mechanism
Lu AF28996 is Lundbeck's investigational small molecule for Parkinson's motor fluctuations. Flexible-dose design tests effect on off-time without exacerbating dyskinesia.
Why It Matters
Motor fluctuations are the most common Parkinson's complication after years of levodopa exposure; every advanced PD patient eventually faces them. Current options (COMT inhibitors, MAO-B inhibitors, amantadine ER) deliver modest off-time reduction. Lundbeck's deep CNS franchise and history with vortioxetine and brexpiprazole make this a watch-and-see asset; if Lu AF28996 shows meaningful off-time benefit, it positions for blockbuster commercial status.
Verified sources
Advanced Modalities
3 trialsSPK-8011QQ AAV Gene Therapy in Adults With Severe or Moderately Severe Hemophilia A
Roche restarts SPK-8011 with a next-generation construct in severe hemophilia A
Timeline
Start: June 30, 2026. Primary completion: July 2031.
Mechanism
SPK-8011QQ is a re-engineered AAV gene therapy delivering Factor VIII (the original SPK-8011 program with capsid/expression cassette optimization). One-time IV infusion designed to provide durable FVIII production.
Why It Matters
Roche restarts SPK-8011 in hemophilia A after the original program development pause, with the next-generation construct. BioMarin's Roctavian (the only approved hemophilia A gene therapy) has had a commercially difficult launch; durability questions and high pricing. Roche entering with an updated construct signals belief that an improved AAV can overcome Roctavian's market reception challenges. Combined with Edition 11's Affinia BAG3 DCM and Edition 10's NAAVIGATE DR, AAV reach continues to widen.
Verified sources
MT027 Intracerebroventricular Universal CAR T (B7H3) in Recurrent / Progressive Glioblastoma
First universal CAR T with direct CNS delivery in GBM; novel modality on a validated solid-tumor target
Timeline
Start: June 30, 2026. Primary completion: December 2028.
Mechanism
MT027 is a universal (allogeneic, off-the-shelf) CAR T targeting B7H3, administered via intracerebroventricular injection in patients with recurrent or progressive WHO Grade 4 glioblastoma.
Why It Matters
Solid-tumor CAR T has struggled with two structural problems: autologous manufacturing cost/time and CNS delivery in brain tumors. MT027 addresses both; allogeneic UCAR T (off-the-shelf) plus intracerebroventricular delivery directly into the CNS. If even modest efficacy is shown in r/r GBM (one of oncology's deadliest indications), the entire allogeneic CAR T + intrathecal delivery framework becomes the template for the next solid-tumor CAR T wave. Allogene, Adicet, and Caribou are all watching.
Verified sources
ZM-02 Gene Therapy in Advanced Retinitis Pigmentosa
Zhongmou's first-in-human ocular AAV in a high-need rare-disease segment
Timeline
Start: June 25, 2026. Primary completion: December 2029.
Mechanism
Subretinal injection of ZM-02 (target gene/construct not yet disclosed publicly), with sham-controlled design across low, high, and selected-dose cohorts. First-in-human program for Zhongmou.
Why It Matters
Retinitis pigmentosa affects ~100K people in the US and lacks effective therapies for most genotypes. Luxturna (Spark/Roche) validated AAV gene therapy in RPE65-associated RP, but the broader RP population remains untreated. ZM-02 represents another Chinese biotech entering retinal gene therapy alongside Shanghai Vitalgen (VGN-R08b in PD, Edition 10). Combined with AbbVie's NAAVIGATE (DR) and Adverum's Ixo-vec (nAMD), the retinal gene therapy field is now four-sponsor + multi-target.
Verified sources
Signal Convergence
Obesity competition becomes structurally crowded
Roche opens two parallel programs (Petrelintide + Enicepatide Phase 2 combo, plus a separate Enicepatide program in Chinese obesity). Boehringer Ingelheim opens BI 3034701 Phase 2b at 57 sites. Novo Nordisk runs CagriSema presentation comparability at 1,400 patients / 116 sites; its fourth concurrent late-stage obesity Phase 3. The post-GLP-1 era has arrived: amylin combos, GIP antagonist conjugates, and oral umbrella programs compete in the same operational moment.
BCMA in 1L MM becomes a multi-asset race
Heidelberg's Teclistamab quadruplet follows Regeneron's Linvoseltamab (Edition 11) into newly diagnosed transplant-eligible MM. Two BCMA bispecifics, two design frameworks (Linvo replaces dara; teclistamab adds to dara), two sponsors moving in 30 days. Daratumumab's 1L grip is under simultaneous attack from competing strategies.
FXI mAb expansion continues at mega-program scale
Regeneron's REGN7508 opens ROXI-CAT-II in cancer-associated VTE (1,600 patients); after the Edition 10 ROXI-PALISADE PAD program (7,050 patients). One sponsor running two mega Phase 3s on the same FXI antibody in different indications. Combined program enrollment now exceeds 8,600. Anti-FXI antibodies are the most contested next-gen anticoagulant class; and Regeneron is the most committed at the antibody modality.
Solid-tumor CAR T diversifies into universal + intrathecal delivery
T-MAXIMUM's MT027; universal (allogeneic) CAR T targeting B7H3, delivered intracerebroventricularly in recurrent glioblastoma; addresses solid-tumor CAR T's two largest structural barriers in one design. Continues the broader CAR T modality expansion across Editions 8 to 12: autoimmune (BMS Breakfree-SSc, Cartesian Descartes-08, Cabaletta CABA-201 MS), solid-tumor target diversity (DLL3 via DJI136), and now universal cellular therapy in CNS oncology.
AAV gene therapy reach widens; hemophilia A revival
Roche restarts the SPK-8011 program (acquired from Spark) with the next-generation SPK-8011QQ construct in severe hemophilia A. BioMarin's Roctavian commercial reception hasn't deterred re-entry. Combined with Edition 11's Affinia BAG3 DCM (first AAV for hereditary cardiomyopathy) and Edition 10's NAAVIGATE in DR, AAV is now in five new therapeutic categories across three editions.
Underlying truth: the platform proliferation accelerates. ADC, BCMA bispecific, FXI antibody, AAV, universal CAR T, GLP-1+amylin combination; every major modality is in simultaneous Phase 2/3 expansion. The bottleneck is no longer "does the modality work"; it is "which sponsor lands the first three indications first."
On Verification
Every trial in this edition is anchored to three deterministic, verifiable sources sitting inline under each entry: the trial's ClinicalTrials.gov record, its WHO ICTRP cross-listing (deterministic URL pattern), and the sponsor's evergreen clinical trials search portal where one exists. Dated press-release URLs are intentionally not embedded inline because they 404 over time. All 15 trials in this edition have start dates verified to fall within June 16 to June 30, 2026, and none repeat from Editions 1 to 11.
About Trial Watch
Trial Watch is Kitsa's twice-monthly U.S. clinical intelligence briefing. It captures high-signal clinical trial events and interprets where science, capital, and strategy are converging.
Keep exploring
Recommended next
- Blog
11 Early-Phase Trials and Design Frameworks to Reduce Design Risk
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
- Blog
4 AI Misconceptions in Clinical Trials You Cannot Afford to Ignore
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
- Blog
7 Questions to Ask Before Choosing an AI Patient Screening Solution
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
- Glossary
Accelerated Approval
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.